AML-CR复发的根本原因是体内残留白血病细胞，调动机体免疫能力清除残留白血病细胞是AML-CR的重要治疗思路，但患者免疫功能低下，难以启动有效的肿瘤免疫应答。抗原提呈细胞DC内噬肿瘤抗原后形成MHC-抗原肽复合物刺激T细胞，T细胞在共刺激分子刺激下启动免疫应答。本项目以微小残留白血病“正气虚弱、余毒留伏阴分”的病机理论及“扶正透毒祛毒”的治疗理论为指导，采用血清药理学、细胞培养、流式细胞技术、RT-PCR等方法与技术，通过研究B7-1/2信号通路对AML-CR患者自体CD34+细胞源DC生物学效应的影响，探索B7-1/2信号通路在AML-CR患者肿瘤免疫应答的作用，探讨AML-CR患者CD34+细胞源DC发挥肿瘤免疫功能的作用机制，进一步通过扶正透毒复方中药干预研究，探讨中医药治疗MRD-L的机制，探索中医药治疗MRD-L的新方法，为研发有效的中药制剂打基础。

The primary cause for the post recurrence of AML-CR is the minimal residuals of leukemic cells in corpora. An important idea to cure MRD-L is to activate the organism’s immunologic function to eliminate the residuals of leukemic cells; but given the patient’s lower immunologic function, it is hard to trigger the effective tumor immune response. After the antigen presenting cells DC endocytose tumor antigens, the MHC-antigen peptide compounds are formed to stimulate T cells,which activate immune response under the stimulation of co-stimulatory molecules.Under the guidance of minimal residual disease in leukemia (MRD-L) theory of pathological mechanism “the body is weak, there leaves pernicious influence in the Yin components” and the therapeutic theory “strengthening the body resistance and detoxicating”, thods and techniques such as serum pharmacology,cell culture, flow cytometry, RT-PCR and so forth are adopted in this project. By researching the influence of the signal access of B7-1/2, a member of co-stimulatory molecular family B7, upon the biological effect of AML-CR patients’ autologous source of CD34+ cells DC, the effect of B7-1/2 signal access on AML-CR patients’ tumor immune response is xplored. The mechanism of action of AML-CR patients’ source of CD34+ cells DC playing tumor immunologic function is explored and iscussed. Further, through the research on compound prescriptions intervention, the mechanism to cure MRD-L with TCM is explored and discussed, and new methods to cure MRD-L with TCM are explored so as to lay a foundation for developing effective TCM preparations.